Abstract
A total of 56 consecutive patients with metastatic colorectal cancer received treatment with 5-fluorouracil (5-FU) given at 425 mg/m2 by rapid intravenous infusion, immediately preceded by leucovorin (LV) given at 20 mg/m2, with cycles being repeated every 4 weeks. Of 48 evaluable patients undergoing this treatment, a tumor response was observed in 16 (33%); a complete response, in 2 (4%); and a partial response, in 14 (29%). The median survival was 8.5 months for all patients and 16.5 months for responders. An improvement in symptoms was seen in 9 (26%) of 34 symptomatic patients. In all 15 (27%) of 44 evaluable patients showed an improvement in performance status. The most significant toxicity attributable to the treatment was mucositis of grade 3 or 4, seen in 27% of the patients. Altogether, 2 patients (3.5%) were hospitalized for treatment-related toxicity. We conclude that the combination of 5-FU and low-dose LV is active in advanced colorectal cancer and is associated with acceptable toxicity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Advanced Colorectal Cancer Meta-Analysis Project (1992) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10: 896
Allan S, Forgeson G, Wynne C, Thompson P, Perez D (1991) 5-Fluorouracil (5 FU) and low dose folinic acid (FA) in the treatment of colorectal carcinoma. In: Annual scientific meeting, December 4–6, 1991. From laboratory to clinic-an integrated approach to cancer research and therapy. Clinical Oncology Society of Australia Inc., Sydney, Australia, p 106
Borner MM, Sartor O (1993) More is not always better: a case for low dose leucovorin (letter). J Clin Oncol 11: 382
Buroker TR, O’Connell MJ, Wieand HS, Krook JE, Gerstner JB, Mailliard JA, Schaefer PL, Levitt R, Kardinal CG, Gesme DH (1994) Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12: 14
Cricor A, Hartoni A, Guaraldi H (1988) Randomized clinical trial of 5FU + folinic acid vs 5FU in advanced gastrointestinal cancers. Proc ESTRO 13: 427
Di Constanzo F, Bartolucci R, Sofra M (1989) 5-Fluorouracil alone vs high dose folinic acid and 5 FU in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research (GOIRC) (abstract). Proc Am Soc Clin Oncol 8: 410
Doroshow JH, Multhauf P, Leong L, Margolin K, Litchfield T, Akman S, Carr B, Bertrand M, Goldberg D, Blayney D, Odujinrin O, DeLap R, Shuster J, Newman E (1990) Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 8: 451
Evans RM, Laskin JD, Hakalo HT (1981) Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res 41: 3288
Erlichman C, Fine S, Wong A. Elhakim T (1988) A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6: 569
Hryniuk WM, Bush H (1984) The importance of dose intensity in the chemotherapy of metastatic breast cancer. J Clin Oncol 2: 1281
Lennancor R, Pancers S, Aituri F (1991) Folinic acid + 5-fluorouracil (5FU) versus low dose 5FU in advanced colorectal cancer. Phase III study of GISCARD (Italian Group for the Study of Digestive Tract Cancer). Ann Oncol 2: 673–690
Miller AB, Hoogstraten B, Staguet H, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207
Nobile MT, Rosso R, Sertoli MR, Rubagotti A, Vidili HG, Guglielmi A, Venturini M, Canobbio L, Fassio T, Gallo L, Galligioni E, Gallotti P, Bruzzi P, Sobrero A (1992) Randomised comparison of weekly bolus 5-fluorouracil with or without leucovorin in metastatic colorectal carcinoma. Eur J Cancer 28A: 1823
Petrelli N, Herrera L, Rustum Y, Burke P, Creaven P, Stulc J, Emrich J, Mittelman A (1987) A prospective randomized trial of 5-fluorouracil vs 5-fiuorouracil and high dose leucovorin + 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5: 1559
Petrelli N, Douglass HO, Herrera L, Russel D, Stablein DH, Bruckner HW, Mayer RJ, Schinella R, Green MD, Muggia FM (1989) The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 7: 1419
Poon MA, O’Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Krook JE, Mailliard JA, Laurie JA, Tschetter LK, Wiesenfeld M (1989) Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7: 1407
Poon MA, O’Connel MJ, Wieand HS, Krook JE, Gerstner JB, Tschetter LK, Levitt R, Kardinal CG, Mailliard JA (1991) Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9: 1967
Valone FH, Friedman MA, Wittlinger PS, Drake ST, Eisenberg PD, Malec M, Hannigan JF, Brown BW Jr (1989) Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group. J Clin Oncol 7: 1427
Waxman S, Bruckner H (1982) The enhancement of 5-fluorouracil antimetabolic activity by leucovorin, menadione, and alpha-tocopherol. Eur J Cancer Clin Oncol 18: 685
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fried, G., Tsalik, M., Stein, M. et al. 5-Fluorouracil and low-dose leucovorin in metastatic colorectal cancer: a pilot study. Cancer Chemother. Pharmacol. 35, 437–440 (1995). https://doi.org/10.1007/s002800050259
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s002800050259